ClaraT Whitepaper

Within this article, we provide evidence of the ability of claraT  to robustly identify the biologies underlying several Hallmarks of cancer. This is shown by a retrospective case study in malignant melanoma which represents poor prognostic disease (5-yr survival 15-20%). We applied claraT to the TCGA melanoma dataset to identify targetable biologies within both the study cohort and individual tumour samples.

This white paper retrospective study demonstrates how simultaneous analysis of multiple gene expression signatures (GES) (n=62 in this study) can identify robust biologies through consensus readouts. Almac’s claraT reporting solution may have value in the identification of reliable biomarkers for clinical trials and could inform combination strategies for targeting key biologies.

View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies